Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A580 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A580 | DRUG | Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels. |
HMPL-A580 is an investigational small molecule oncology drug being developed by HUTCHMED (China) Limited for the treatment of advanced or metastatic solid tumors in adults. It is currently in Phase 2 development and has not been approved for any indication.
HMPL-A580 is being studied for use in adults with advanced or metastatic solid tumors. It is an investigational therapy and is not approved for the treatment of solid tumors or any other condition.
HMPL-A580 targets EGFR, a protein target. EGFR is a receptor tyrosine kinase that plays a role in cell growth and survival in solid tumors. HMPL-A580 is a small molecule designed to act on this target.
HMPL-A580 is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. HUTCHMED is the sponsor of the clinical program evaluating the drug in adult patients with advanced or metastatic solid tumors.
HMPL-A580 is in Phase 2 development. It is an investigational drug and is not FDA approved. The ongoing clinical program is a Phase 1/2a study, and no trials of HMPL-A580 have been completed.
HMPL-A580 is being evaluated in one active clinical trial, NCT07396584, titled A Phase I/IIa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor. The trial is not yet recruiting and is planned to enroll 186 participants.